Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Crystalys is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of gout. Backed by Novo Holdings and Catalys Pacific, our team combines world-class expertise in gout drug development with a mission to deliver safer, more effective therapies. Our lead candidate, Dotinurad, a next-generation URAT1 inhibitor with best-in-class potential, is advancing into global Phase 3 trials as a second-line ther...
Crystalys is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of gout. Backed by Novo Holdings and Catalys Pacific, our team combines world-class expertise in gout drug development with a mission to deliver safer, more effective therapies. Our lead candidate, Dotinurad, a next-generation URAT1 inhibitor with best-in-class potential, is advancing into global Phase 3 trials as a second-line therapy, supported by extensive clinical data from approvals in multiple Asian markets.

List your booth number for exhibitions, ask us